Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug…
In addition, the design phase is underway for a Drug Substance (DS) modular facility planned for the Singapore CRDMO hub. In addition, the design phase is underway for a Drug Substance (DS) modular facility planned for the Singapore CRDMO hub. Dr.Chris Chen, CEO of WuXi Biologics,commented, "The growing diversity of the global biologics pipeline and continued advances in bioprocessing call for innovative, highly efficient, and adaptable facilities designed to meet evolving...
PR Newswire
29/07/2025
Tsingke Biotech Hosts 2025 Small Nucleic Acid Therapeutics Roundtable in Beijing
The forum featured keynote presentations and a high-level panel discussion addressing the critical challenges and opportunities shaping the future of RNA-based therapeutics. Topics included non-hepatic targeting strategies, aptamer screening, CMC compliance, IP strategies, and next-generation delivery platforms. The forum featured keynote presentations and a high-level panel discussion addressing the critical challenges and opportunities shaping the future of RNA-based therapeutics. Topics...
PR Newswire
29/07/2025
LIfT BioSciences announces grant of €12 million from Ireland’s Disruptive…
Galway, London,29 July 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces a grant of €12 million has been awarded from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Neutrophils (IMANs), designed to overcome treatment resistance in solid tumours, through first-in-human clinical trials expected to start in Q4 2026.The €12 million grant, the...
Nasdaq GlobeNewswire
29/07/2025
Tigermed Completes Acquisition of Japanese CRO Micron
As the first imaging CRO in Japan, Micron has built a strong reputation for technology excellence and pioneering practices in imaging biomarkers, AI-powered imaging support, and long-standing client trust. As the first imaging CRO inJapan, Micron has built a strong reputation for technology excellence and pioneering practices in imaging biomarkers, AI-powered imaging support, and long-standing client trust. Following the acquisition, Micron will be integrated into Tigermed's global...
PR Newswire
29/07/2025
Indonesia’s Ministry of Health and Philips to deliver nationwide coverage of…
Long-term multiyear agreements will see Philips installing its advanced Azurion image-guided therapy systems nationwide across all provinces, including rural and remote areasInitiative brings minimally invasive care to millions of cardiac, stroke and cancer patients in IndonesiaCombines cutting-edge treatment technology, services and training to strengthen Indonesia’s health infrastructureAmsterdam, the Netherlands and Jakarta, Indonesia –In a major step toward transforming...
Nasdaq GlobeNewswire
29/07/2025
Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold…
Study to evaluate the efficacy and safety of fosmanogepix in adults with invasive mold infectionsStudy completion expected in Q1 2028 Allschwil, Switzerland, July 29, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the initiation of FORWARD-IM, a phase 3 registrational study evaluating the efficacy and safety of its...
Nasdaq GlobeNewswire
29/07/2025
Philips builds strong order intake momentum and drives margin expansion in Q2
Q2 2025 Group HighlightsComparable order intake growth 6%Group sales EUR 4.3 billion, reflecting 1% increase in comparable salesIncome from operations EUR 400 millionAdjusted EBITA margin increased 130 bps to 12.4% of salesFree cash flow increased to EUR 230 millionPhilips increases full year 2025 outlook for Adjusted EBITA margin and free cash flow; reiterates comparable sales growth outlookRoy Jakobs, CEO of Royal Philips:“We are focused on driving profitable growth...
Nasdaq GlobeNewswire
29/07/2025
Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by…
Key Takeaways from the Alpha-synuclein Inhibitors Market Report Key Takeaways from the Alpha-synuclein Inhibitors Market Report Discover which indication is expected to grab the major alpha-synuclein inhibitors market share @Alpha-synuclein Inhibitors Market Report Alpha-synuclein Inhibitors Market Dynamics The alpha-synuclein inhibitors market is driven by thegrowing prevalence of neurodegenerative disorderssuch as Parkinson's disease, Lewy body dementia, and multiple...
PR Newswire
28/07/2025
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
The publication will be followed by an investor conference call and webcast on Tuesday August 5, 2025 at 8:00 AM ET / 2:00 PM CET. The call will include the Company’s second quarter results and an update on business activities.Details for the call are as follows: Dial in information: Domestic: +1-800-343-5172International: +1-203-518-9856Conference ID: CLLSQ2Webcast Link:https://viavid.webcasts.com/starthere.jsp?ei=1727030&tp_key=10a62ee950About Cellectis Cellectis...
Nasdaq GlobeNewswire
28/07/2025
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated InformationChâtillon, France, July 28, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2025: 210,069...
Nasdaq GlobeNewswire
28/07/2025
Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep…
Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep MedicineMont-Saint-Guibert, Belgium – July 28, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that data from its DREAM pivotal study was published online in the Journal of Clinical Sleep Medicine. The DREAM pivotal...
Nasdaq GlobeNewswire
28/07/2025
Piramal Pharma Limited Announces Results for Q1FY26
Key Highlights for Q1FY26 Nandini Piramal, Chairperson, Piramal Pharma Limitedsaid, " Excluding the impact of destocking in one large on-patent commercial product, our CDMO business delivered mid-teen revenue growth during the quarter accompanied by improvement in EBITDA margin, especially at our overseas sites. Growth in our CHG business is also expected to pick up for the remaining part of the year given the timing of some of the institutional orders. Our consumer business...
PR Newswire
28/07/2025
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER…
The results were reported for the first time today at the Alzheimer's Association International Conference (AAIC) 2025 in Toronto and online. "Effects Of Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The U.S. POINTER Randomized Clinical Trial," was published in The Journal of the American Medical Association (JAMA) simultaneously with the report at AAIC 2025. The results were reported for the first time today at theAlzheimer's…
PR Newswire
28/07/2025
EssilorLuxottica: Q2/H1 2025 Results - Sound revenue growth at 7.3% in Q2 and…
Sound revenue growth at 7.3% in Q2 and H1AI glasses speeding up furtherGroup’s revenue growing 7.3% in both Q2 and H1 (constant exchange rates 1 )North America accelerating in PS, DTC keeping a solid growth paceEMEA confirming the strong performance of PS and DTC, as the best region for the GroupAI glasses Ray-Ban Meta up more than 200% in sales in H1AI glasses Oakley Meta on the blocks, successful launch of the 50 thanniversary editionNuance Audio already...
Nasdaq GlobeNewswire
28/07/2025
Press release: Transparency Notification from Shareholders
Transparency Notification from ShareholdersGhent, Belgium – 28 July 2025 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entities listed below, notifying the number of voting rights attached to the shares mentioned next to their name in the table below…
Nasdaq GlobeNewswire
28/07/2025
Lumibird: H1 2025 revenue up 9.0% to EUR106.8 million
Lannion, 28 July 2025 - 5.45pm H1 2025 revenue up 9.0% to €106.8 million The Lumibird Group (FR0000038242 - LBIRD), European leader in laser technologies, posted consolidated revenue of €106.8 million in the first half of 2025, up 9% (+9.1% on a like-for-like basis): +8.6% for the Photonics division and +9.4% for the Medical division…
Actusnews Wire
28/07/2025
Biosurgery Market worth US$21.59 Billion by 2030 with 6.4% CAGR |…
Browse in-depth TOC on "Biosurgery Market" Browse in-depth TOC on "Biosurgery Market" 450 - Tables 60 - Figures 350 - Pages By product,the biosurgery market is segmented into bone-graft substitutes, soft-tissue attachments, hemostatic agents, surgical sealants and adhesives, adhesion barriers, and staple-line reinforcement agents. The surgical sealants and adhesives segment is anticipated to exhibit the most rapid growth within the biosurgery market during the forecast...
PR Newswire
28/07/2025
Dietary Supplements Market to Reach USD 351.8 Billion by 2032, Growing at 8.5%…
Download Sample Pages of the Report: https://www.skyquestt.com/sample-request/dietary-supplements-market Download Sample Pages of the Report:https://www.skyquestt.com/sample-request/dietary-supplements-market Dietary Supplements Market Key Growth Drivers: What are the Recent Developments in Dietary Supplements Market? Speak to our Analyst: https://www.skyquestt.com/speak-with-analyst/dietary-supplements-market Major Challenges in Dietary Supplements Market Industry ...
PR Newswire
28/07/2025
Hemostats Market is expected to generate a revenue of USD 4.25 Billion by 2031…
The Hemostats Market is witnessing strong growth due to its crucial role in surgical bleeding control. With advancements in surgical techniques and growing healthcare expenditure, demand for efficient hemostatic agents is rising globally, especially across North America and Europe. The Hemostats Market is witnessing strong growth due to its crucial role in surgical bleeding control. With advancements in surgical techniques and growing healthcare expenditure, demand for efficient hemostatic...
PR Newswire
28/07/2025
Siemens Healthineers Receives Frost & Sullivan's 2025 North America Company of…
Guided by a focused growth strategy centered on organic development, digital innovation, and deep customer partnerships, Siemens Healthineers shapes the future of advanced visualization (AV) by delivering scalable, integrated platforms that enhance diagnostic confidence and operational agility. The company's sustained investment in intelligent imaging software and adaptive workflow integration has enabled it to lead in a sector increasingly defined by complexity, interoperability, and…
PR Newswire
28/07/2025
Introducing Antigravity: The Future of Aerial Exploration and Storytelling
"Today, most drones are tools. With Antigravity, we're aiming higher," says BC Nie, Head of Marketing at Antigravity. "While others compete on specs, we've flipped the script, reimagining what a drone should be able to do. The result is something that empowers real emotion and enables experiences like freedom, creativity, and discovery for everyone." " Today, most drones are tools. With Antigravity, we're aiming higher, " says BC Nie, Head of Marketing at…
PR Newswire
28/07/2025
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the…
"The presentation of brain-derived pTau data at AAIC is a testament to the power of the NULISA sensitivity and specificity and our team's dedication to advancing biomarker development for neurodegenerative diseases," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. "The presentation of brain-derived pTau data at AAIC is a testament to the power of the NULISA sensitivity and specificity and our team's dedication to advancing biomarker development for…
PR Newswire
28/07/2025
Cumulus Neuroscience Presents Data at AAIC 2025 Annual Meeting and Technology…
Cumulus presented a poster titled, "Frequent at-home multimodal measurements are more sensitive to progression than the gold-standard clinic-based ADAS-Cog composite scale" which featured data confirming repeated home-based digital cognitive endpoints are more sensitive to disease progression than the ADAS-Cog 13 composite benchmark, the primary cognitive scale used in Alzheimer's clinical trials today to determine drug efficacy. Additionally, passive electroencephalography (EEG)…
PR Newswire
28/07/2025
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up…
Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic Value The company intends to establish a dedicated subsidiary, named “American BNB Strategy,” to lead its digital asset investment and management initiatives. Through this planned vehicle, Liminatus aims to raise and deploy up to $500 million in phases, targeting strategic, long-term investments in BNB coin...
Nasdaq GlobeNewswire
28/07/2025
Altri Comunicati
